Open Orphan plc announced the appointment of Yamin 'Mo' Khan as an Independent Non-Executive Director to the Board of Open Orphan with immediate effect. Mo will also Chair both the Audit and Risk and Nomination Committees. He previously worked at Pharm-Olam International, a global CRO, from 2000-2019 across a variety of senior positions including Executive Vice President of Clinical Development and Global Director of Clinical Operations. As part of Mo joining the Board, Michael Meade is stepping down from the Board with immediate effect. Michael joined the Board of Open Orphan as part of the acquisition of hVIVO and helped to steer the Company to the stronger and more successful position that it occupies today.